Blood Based Risk Evaluation With AI for Targeted Primary Health Care in Early Lung Cancer Detection
Summary
A prospective, non-randomized feasibility study (NCT07552584) registered April 27, 2026 evaluates blood sample and machine learning-based risk stratification for lung cancer in patients with COPD. COPD patients will be recruited in general practice settings, with blood samples analyzed by an AI/machine learning model; high-risk patients will be referred for low-dose CT scans. The primary objective is to assess feasibility of AI and DNA methylation-based risk stratification for lung cancer detection in primary care.
“The study is a prospective, non-randomized feasibility study evaluating blood sample and machine learning-based risk stratification for lung cancer in patients with COPD (chronic obstructive pulmonary disease).”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
ClinicalTrials.gov registered a prospective feasibility study evaluating AI and machine learning-based risk stratification using blood samples for early lung cancer detection in COPD patients. The study will enroll patients from general practice, analyze blood samples via a machine learning model, and refer high-risk patients for low-dose chest CT. Primary endpoints assess feasibility of the AI-based risk stratification approach; secondary endpoints include safety, quality of life, patient and physician perspectives, and health economic consequences.
Healthcare providers and clinical investigators should note this trial represents an emerging application of AI and DNA methylation analysis for lung cancer screening in a primary care setting targeting a high-risk COPD population.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Blood Based Risk Evaluation With AI for Targeted Primary Health Care in Early Lung Cancer Detection
N/A NCT07552584 Kind: NA Apr 27, 2026
Abstract
The study is a prospective, non-randomized feasibility study evaluating blood sample and machine learning-based risk stratification for lung cancer in patients with COPD (chronic obstructive pulmonary disease).
Patients with COPD will be recruited in general practice, where they will have a blood sample drawn. All data will be analyzed by the machine learning model, and patients with increased risk of lung cancer will be referred for a low-dose CT scan of the chest.
The primary objective of the study is to evaluate the feasibility of AI and DNA methylation-based risk stratification for lung cancer in patients with COPD in a primary care setting.
The secondary objectives are to evaluate the safety of the risk stratification approach, the potential effects on quality of life and wellbeing, to gain insight into the patient and physician perspectives, and to estimate the health economic consequences.
Conditions: Lung Cancer (Diagnosis)
Interventions: Risk stratification
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.